Subtype
Malignant Pleural Neoplasm
CI-CAN-00001168Explore in graph →
26 active trials4 approved drugs6 evidence items
- NCIt
- C3547
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001168Explore in graph →
Clinical trials
124 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (18)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01870609 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma(COMMAND) | terminated | Phase 2 | 344 | Verastem, Inc.INDUSTRY | 15 | Jan 30, 2017 | clinicaltrials |
| NCT02755675 | uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung | unknown | Phase 2 | 120 | Rigshospitalet, DenmarkOTHER | 1 | Nov 21, 2016 |
| clinicaltrials |
| NCT00165503 | Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate | terminated | Phase 2 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 9, 2016 | clinicaltrials |
| NCT01769547 | A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy(DOVE-M) | terminated | Phase 2 | 12 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 17, 2015 | clinicaltrials |
| NCT02497053 | Four Versus Six Cycles of Pemetrexed/Platinum for MPM | unknown | Phase 2 | 70 | Ain Shams UniversityOTHER | 1 | Jul 14, 2015 | clinicaltrials |
| NCT01024946 | Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity | completed | Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 12, 2015 | clinicaltrials |
| NCT01279967 | A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma(ADAM) | unknown | Phase 2 | 70 | Barts & The London NHS TrustOTHER | 1 | Nov 20, 2014 | clinicaltrials |
| NCT00165516 | Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate | completed | Phase 2 | 85 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 27, 2014 | clinicaltrials |
| NCT01353482 | A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma(MESO-02) | withdrawn | Phase 1 / Phase 2 | 0 | University College, LondonOTHER | 0 | Mar 22, 2012 | clinicaltrials |
| NCT01243632 | Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment | completed | Phase 2 | 78 | Institute of Oncology LjubljanaOTHER | 1 | Nov 18, 2010 | clinicaltrials |
| NCT00272558 | Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma | completed | Phase 2 | 40 | Rigshospitalet, DenmarkOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00886028 | Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma | unknown | Phase 2 | 31 | National Institute of CancerologíaOTHER_GOV | 1 | Apr 22, 2009 | clinicaltrials |
| NCT00386815 | Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma | completed | Phase 2 | 20 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 11, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Jan 30, 2017source: clinicaltrials